USPTO serial 79426106
STAR-CRISPR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 17, 2026
- Examiner
- EISNACH, MICHAEL PATRICK
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with STAR-CRISPR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
BE
BE
BE
BE
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for research purposes; reagents used in science; reagents for scientific purposes; reagents for medical research; laboratory reagents for scientific use; chemical reagents for scientific purposes; reagents for scientific or medical research use; chemical reagents for use in genetic research; chemical reagents for use in biotechnology, other than for medical or veterinary use; specialized reagents for genome editing for scientific, research, and laboratory use; modified cells, in particular genetically modified ips (induced pluripotent stem) cells and differentiated cells derived therefrom, for research or scientific purposes; cell cultures, cell culture systems and cryopreserved genetically modified ips cells for scientific and industrial research purposes; cell cultures, and cryopreserved cells ips cells other than for medical or veterinary use; Biological preparations for use in cell cultures, other than for medical or veterinary purposes, namely, cell culture agents for use in the biotechnology industry and cell material for use in combination with human cells, including genetically modified ips or differentiated stem cells | ACTIVE | — |
| 005 | Medical diagnostic reagents; clinical medical reagents; clinical diagnostic reagents for medical use; reagents for use in medical genetic testing; cells for medical use; genetic identity tests comprised of reagents for medical purposes; specialized reagents for genome editing for medical and medical clinical use; modified cells, in particular genetically modified ips (induced pluripotent stem) cells and differentiated cells derived therefrom, for medical or veterinary use; cell cultures and cell culture systems, and cryopreserved pluripotent stem cells for medical or veterinary use; genetically modified ips (induced pluripotent stem) cells for use in generating other cells for therapeutic purposes; cell cultures and cell culture systems, and cryopreserved genetically modified pluripotent stem cells for sub cultivation of cells, for medical or veterinary use | ACTIVE | — |
| 040 | Custom manufacturing of iPS derived cells, and iPS derived cell therapy and manufacturing processes for others, namely, manufacturing of the foregoing cells in GMP-based facilities; custom manufacture of therapeutic cells, medicines, cell therapies and gene edited cell therapies for others, including manufacturing in GMP-based facilities; custom manufacture of cellular therapies, including manufacturing in GMP-based facilities; manufacturing of cell lines being modified cells with specific genetic edits for use in generating other cells | ACTIVE | — |
| 042 | Structural and functional analysis of genomes; research and development in the field of microorganisms and cells; research in the field of gene editing technology; genetic research; gene therapy research; scientific research in the field of genetics and genetic engineering; research in the field of gene therapy; research in the field of genetic diseases; scientific research relating to genetics; biotechnology research; biotechnology testing; preparation of reports in the biotechnology field; research and testing of cell-based products, in particular therapeutic products; research, optimization and testing of cell production processes; laboratory research in the field of biotechnology using genetically modified ips (induced pluripotent stem) cells and differentiated cells derived therefrom; scientific research, design and development of scientific cell culture, cell therapy and gene edited cell therapy; scientific research, design and development of cell culture, cell therapy and gene edited cell therapy, manufacturing systems and manufacturing processes for others; platform as a service (PAAS) services featuring computer software platforms for custom manufacturing of cell-based products in the field of cell therapy, and cell therapy development; providing temporary use of online non-downloadable computer software platform for the management of manufacturing of cell-based therapies, namely, the associated technology, processes, and data analytics capabilities for process optimization and quality control | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Celyntra Therapeutics SA
- Other trademarks owned by Celyntra Therapeutics SA
- Other trademarks owned by Celyntra Therapeutics SA
- Other trademarks owned by Celyntra Therapeutics SA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named STAR-CRISPR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 27, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 27, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 25, 2026 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jun 17, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 17, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 17, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 27, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 27, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 21, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 6, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 5, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 5, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 5, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 22, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 5, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 5, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 17, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 16, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 3, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 22, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 22, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 19, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |